Psychotropic drug prescription in a psychiatric university hospital in Germany

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 6, 2006, Pages 1109-1116

  Davids, Eugen ^a   Bunk, Christine ^a   Specka, Michael ^a   Gastpar, Markus ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Polypharmacy; Psychotropic drug; Retrospective survey

Indexed keywords

ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; DISULFIRAM; FLUMAZENIL; LITHIUM; METHADONE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABUSE; DRUG MONITORING; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MONOTHERAPY; MOOD DISORDER; ORGANIC PSYCHOSYNDROME; PERSONALITY DISORDER; POLYPHARMACY; PRESCRIPTION; SCHIZOPHRENIA; SUBSTANCE ABUSE; UNIVERSITY HOSPITAL;

ADULT; AGE FACTORS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GERMANY; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HOSPITALS, UNIVERSITY; HUMANS; LENGTH OF STAY; MALE; MENTAL DISORDERS; PRESCRIPTIONS, DRUG; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 33745279103     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.04.015     Document Type: Article

References (34)

1. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 158 (2001) S1-S52
2. Ananth J., Parameswaran S., and Gunatilake S. Antipsychotic polypharmacy. Curr Pharm Res 10 (2004) 2231-2238
3. Anil Yagcioglu A.E., Kivircik Akdede B.B., Turgut T.I., Tumuklu M., Yazici M.K., Alptekin K., et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66 (2005) 63-72
4. Barbui C., Danese A., Guaiana G., Mapelli L., Miele L., Monzani E., et al. Prescribing second-generation antipsychotics and the evolving standard care in Italy. Pharmacopsychiatry 35 (2002) 239-243
5. Centorrino F., Eakin M., Bahk W.M., Kelleher J.P., Goren J., Salvatore P., et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 159 (2002) 1932-1935
6. Centorrino F., Goren J.L., Hennen J., Salvatore P., Kelleher J.P., and Baldessarini R.J. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161 (2004) 700-706
7. Centorrino F., Fogarty K.V., Sani G., Salvatore P., Cimbolli P., and Baldessarini R.J. Antipsychotic drug use: McLean Hospital, 2002. Hum Psychopharmacol 20 (2005) 355-358
8. Covell N.H., Jackson C.T., Evans A.C., and Essock S.M. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 28 (2002) 17-29
9. Engel R.R., Grohmann R., Rüther E., and Hippius H. Research methods in drug surveillance. Pharmacopsychiatry 37 (2004) S12-S15
10. Ereshefsky L., and Pharm D. Pharmacological and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 60 (1999) S20-S30
11. Frye M., Ketter T., Leverich G., Huggins T., Lantz C., Denicoff K., et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61 (2000) 9-15
12. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., and Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients 1998-2000. J Clin Psychiatry 65 (2004) 1377-1388
13. Grohmann R., Engel R., Ruther E., and Hippius H. The AMSP drug safety programme: methods and global results. Pharmacopsychiatry 37 (2004) S4-S11
14. Grohmann R., Engel R.R., Geissler K.H., and Ruther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37 (2004) S27-S38
15. Grootens K.P., and Verkes R.J. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry 38 (2005) 20-23
16. Hamann J., Ruppert A., Auby P., Pugner K., and Kissling W. Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int Clin Psychopharmacol 18 (2003) 237-242
17. Internationale Klassifikation psychischer Störungen. ICD-10, Kapitel V (F), Weltgesundheitsorganisation (1991), Verlag Hans Huber, Göttingen
18. Josiassen R.C., Joseph A., Kohegyi E., Stokes S., Dadvand M., Paing W.W., et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162 (2005) 130-136
19. Leslie D., and Rosenheck R. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry 159 (2002) 1534-1540
20. Levine J., Chengappa K.N.R., Brar J.S., Gershon S., Yablonsky E., Stapf D., and Kupfer D.J. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2 (2000) 120-130
21. Lieb K., Zanarini M.C., Schmahl C., Linehan M.M., and Bohus M. Borderline personality disorder. Lancet 364 (2004) 453-461
22. Markovitz P.J. Recent trends in the pharmacotherapy of personality disorders. J Personal Disord 18 (2004) 90-101
23. Post R.M., Ketter T.A., Pazzaglia P.J., Denicoff K., George M.S., Callahan A., et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl. 11 (1996) 153-180
24. Procyshyn R.M., and Thompson B. Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 37 (2004) 12-17
25. Reus V.I. Rational polypharmacy in the treatment of mood disorders. Ann Clin Psychiatry 5 (1993) 91-100
26. Rittmannsberger H., Meise U., Schauflinger K., Horvath E., Donat H., and Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 14 (1999) 33-40
27. Schmahl C., and Bohus M. Symptom-focussed drug therapy in borderline personality disorder. Fortschr Neurol Psychiatr 69 (2001) 310-321
28. Schussler G., and Muller-Oerlinghausen B. Polypharmacy in psychiatric practice. Compr Psychiatry 25 (1984) 566-574
29. Stahl S.M. Antipsychotic polypharmacy: Part 1. therapeutic option or dirty little secret?. J Clin Psychiatry 60 (1999) 425-426
30. Stahl S.M. Antipsychotic polypharmacy: evidence based or eminence based. Acta Psychiatr Scand 106 (2002) 321-322
31. Voirol P., Robert P.A., Meister P., Oros L., and Baumann P. Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 32 (1999) 29-37
32. Weinmann S., Janssen B., and Gaebel W. Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. J Clin Psychiatry 65 (2004) 1099-1105
33. Zanarini M.C. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep 6 (2004) 66-70
34. Zink M., and Dressing H. Augmenting atypical antipsychotic medications with clozapine. Nervenarzt 76 (2005) 1092-1102